8 minute read
Apr. 15, 2024
ORIC-533: An Orally Bioavailable Monophosphonic Acid Inhibitor of CD73 for the Treatment of Multiple Myeloma
ORIC-533
oral CD73 inhibitor Ph. Ib for multiple myeloma SBDD from literature-reported AMPCP structures ACS Spring 2024 Meeting First Time Disclosure ORIC Pharmaceuticals, South San Francisco, CA
Loading...
